Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Autor: Masarova L; Department of Leukemia., Verstovsek S; Department of Leukemia., Hidalgo-Lopez JE; Department of Hematopathology, and., Pemmaraju N; Department of Leukemia., Bose P; Department of Leukemia., Estrov Z; Department of Leukemia., Jabbour EJ; Department of Leukemia., Ravandi-Kashani F; Department of Leukemia., Takahashi K; Department of Leukemia., Cortes JE; Department of Leukemia., Ning J; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Ohanian M; Department of Leukemia., Alvarado Y; Department of Leukemia., Zhou L; Department of Leukemia., Pierce S; Department of Leukemia., Gergis R; Department of Leukemia., Patel KP; Department of Hematopathology, and., Luthra R; Department of Hematopathology, and., Kadia TM; Department of Leukemia., DiNardo CD; Department of Leukemia., Borthakur G; Department of Leukemia., Bhalla K; Department of Leukemia., Garcia-Manero G; Department of Leukemia., Bueso-Ramos CE; Department of Hematopathology, and., Kantarjian HM; Department of Leukemia., Daver N; Department of Leukemia.

Publikováno v: Blood [Blood] 2018 Oct 18; Vol. 132 (16), pp. 1664-1674. Date of Electronic Publication: 2018 Sep 05.